Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension

Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension

Shigella is the second most deadly diarrheal disease among children under five years of age, after rotavirus, with high morbidity and mortality in developing countries. Currently, no vaccine is widely available, and the increasing levels of multidrug resistance make Shigella a high priority for vacc...

Full description

Bibliographic Details
Main Authors: Francesca Micoli, Omar Rossi, Valentino Conti, Odile Launay, Antonella Silvia Sciré, Maria Grazia Aruta, Usman Nasir Nakakana, Elisa Marchetti, Rino Rappuoli, Allan Saul, Laura B. Martin, Francesca Necchi, Audino Podda
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
Shigella sonnei
GMMA
serum bactericidal activity
dose escalation
booster response
1790GAHB
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.671325/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.671325/full

Similar Items